Evidence map›Paper›PMID 40097434›Full record

ArticleScientific reports2025

Longitudinal association of SGLT2 inhibitors and GLP-1RAs on falls in persons with type 2 diabetes.

Yasuhiro Suzuki, Hiroaki Suzuki, Kazushi Maruo, Takaaki Matsuda, Yuki Murayama, Yoko Sugano, Yoshinori Osaki, Hitoshi Iwasaki, Motohiro Sekiya, Yasushi Hada and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. The use of SGLT2 inhibitors in older people: What is important?Aging clinical and experimental research · 2025
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yasuhiro SuzukiDepartment of Endocrinology and Metabolism, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. minamingasaki2007@yahoo.co.jp.
Hiroaki SuzukiDepartment of Endocrinology and Metabolism, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. suzuki-hiroaki@jissen.ac.jp.
Kazushi MaruoDepartment of Biostatistics, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Takaaki MatsudaTsukuba Clinical Research and Development Organization (T-CReDO), University of Tsukuba, Tsukuba, Ibaraki, Japan.
Yuki MurayamaDepartment of Endocrinology and Metabolism, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan.
Yoko SuganoDepartment of Endocrinology and Metabolism, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan.
Yoshinori OsakiDepartment of Endocrinology and Metabolism, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Hitoshi IwasakiDepartment of Endocrinology and Metabolism, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Motohiro SekiyaDepartment of Endocrinology and Metabolism, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Yasushi HadaDepartment of Rehabilitation Medicine, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Hitoshi ShimanoDepartment of Endocrinology and Metabolism, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Low lean body mass increases fall risk. Some diabetes medications, specifically SGLT2 inhibitors and GLP-1RAs, can cause muscle and body mass loss. This study assessed their association on falls in type 2 diabetes patients. An annual fall survey was conducted for up to 5 years on individuals with type 2 diabetes admitted to our department. Fall risk factors were identified using discrete-time survival analysis. The study observed 471 participants over a median period of 2 years. The participants had a median age of 64 years, with a fall incidence rate of 17.1 per 100 person-years. Independent fall predictors identified were fall history, SGLT2 inhibitor use, and age. The odds ratios (95% confidence intervals) for using SGLT2 inhibitors only, GLP-1RAs only, and both combined were 1.80 (1.10-2.92), 1.61 (0.88-2.84), and 2.89 (1.27-6.56), respectively. SGLT2 inhibitor use was an independent risk factor for falls, while GLP-1RAs' effects were not statistically significant. However, the combined use of SGLT2 inhibitors and GLP-1RAs significantly increased the risk of falls. Therefore, it is important to consider this risk when prescribing these medications to people with type 2 diabetes.

Indexed as

Accidental FallsDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsAgedFemaleHumansIncidenceLongitudinal StudiesMaleMiddle AgedRisk FactorsSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID40097434
PMCPMC11914064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.